Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

Hidemitsu Higashi

Yoshihito Tanaka

Minoru Tanaka

Fujio Kobayashi

Takanobu Kuroita

Maiko Hamada

Masatoshi Kiuchi

Shuzo Takeda

Mamoru Matsuura

Hideo Tomozane

Shuuzou Takeda

Shigeki Kuwahara

The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof as an active ingredient.

Therapeutic agent for ophthalmic disease

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Morpholine compound

The object of the present invention is to provide a compound having a treatment effect based on a chemokine inhibitory activity, which is satisfactory as a pharmaceutical product for oral administration. The present inventors have found that the following benzylpiperidine derivative (the formula (1)) has a chemokine inhibitory activity. Further intensive studies have resulted in successful enhancement of the chemokine inhibitory activity and stability in blood of the present compound, as well as the completion of the present invention. wherein each symbol is as defined in the specification.

Benzylpiperidine compound

Growing community of inventors

Tokyo, Japan

Hidemitsu Higashi